| Literature DB >> 33291363 |
Camille Lachat1, Diane Bruyère2, Amandine Etcheverry3,4,5,6, Marc Aubry3,4,5,6, Jean Mosser3,4,5,6, Walid Warda1, Michaël Herfs2, Elodie Hendrick2, Christophe Ferrand1, Christophe Borg1, Régis Delage-Mourroux1, Jean-Paul Feugeas1, Michaël Guittaut1,7, Eric Hervouet1,7,8, Paul Peixoto1,8.
Abstract
The role of Epigenetics in Epithelial Mesenchymal Transition (EMT) has recently emerged. Two epigenetic enzymes with paradoxical roles have previously been associated to EMT, EZH2 (Enhancer of Zeste 2 Polycomb Repressive Complex 2 (PRC2) Subunit), a lysine methyltranserase able to add the H3K27me3 mark, and the histone demethylase KDM6B (Lysine Demethylase 6B), which can remove the H3K27me3 mark. Nevertheless, it still remains unclear how these enzymes, with apparent opposite activities, could both promote EMT. In this study, we evaluated the function of these two enzymes using an EMT-inducible model, the lung cancer A549 cell line. ChIP-seq coupled with transcriptomic analysis showed that EZH2 and KDM6B were able to target and modulate the expression of different genes during EMT. Based on this analysis, we described INHBB, WTN5B, and ADAMTS6 as new EMT markers regulated by epigenetic modifications and directly implicated in EMT induction.Entities:
Keywords: EZH2; H3K27me3; KDM6B; epigenetics; epithelial mesenchymal transition
Year: 2020 PMID: 33291363 PMCID: PMC7762040 DOI: 10.3390/cancers12123649
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639